Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.340
-0.265 (-16.51%)
At close: Nov 12, 2026, 4:00 PM EST
1.280
-0.060 (-4.48%)
After-hours: Nov 12, 2026, 7:59 PM EST
Fate Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Fate Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.72. The average 1-year stock price forecast is 327.01% higher than the current stock price, while the lowest is $2.50 (+86.57%) and the highest is $8.00 (+497.01%).
Price Target: $5.72 (+327.01%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Fate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Cantor Fitzgerald No rating | Cantor Fitzgerald | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Nov 11, 2026 |
| Wedbush | Wedbush | Buy Reiterates $7 | Buy | Reiterates | $7 | +422.39% | Nov 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 | Buy | Reiterates | $8 | +497.01% | Nov 6, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $3.5 → $3 | Hold | Reiterates | $3.5 → $3 | +123.88% | Nov 6, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Reiterates $2.2 → $2.5 | Hold | Reiterates | $2.2 → $2.5 | +86.57% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
3.55M
from 6.65M
Decreased by -46.53%
Revenue Next Year
4.22M
from 3.55M
Increased by 18.72%
EPS This Year
-0.97
from -1.15
EPS Next Year
-0.97
from -0.97
EPS and Forward PE are based on non-GAAP adjusted numbers.